HEADER HYDROLASE/ANTIBIOTIC 05-MAY-11 3RUN TITLE NEW STRATEGY TO ANALYZE STRUCTURES OF GLYCOPEPTIDE ANTIBIOTIC-TARGET TITLE 2 COMPLEXES COMPND MOL_ID: 1; COMPND 2 MOLECULE: LYSOZYME; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ENDOLYSIN, LYSIS PROTEIN, MURAMIDASE; COMPND 5 EC: 3.2.1.17; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: VANCOMYCIN; COMPND 10 CHAIN: B SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: ENTEROBACTERIA PHAGE T4; SOURCE 3 ORGANISM_TAXID: 10665; SOURCE 4 GENE: E; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: STREPTOMYCES ORIENTALIS; SOURCE 9 ORGANISM_TAXID: 31958 KEYWDS ANTIBIOTIC, GLYCOPEPTIDE, NATIVE PROTEIN LIGATION, FUSION, KEYWDS 2 CARBOXYMETHYLATION OF CYSTEINE, VANCOMYCIN, HYDROLASE-ANTIBIOTIC KEYWDS 3 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR N.J.ECONOMOU,T.M.TOWNSEND,P.J.LOLL REVDAT 4 06-DEC-23 3RUN 1 REMARK REVDAT 3 13-SEP-23 3RUN 1 HETSYN REVDAT 2 29-JUL-20 3RUN 1 COMPND REMARK SEQADV SEQRES REVDAT 2 2 1 HETNAM LINK SITE ATOM REVDAT 1 06-JUN-12 3RUN 0 JRNL AUTH N.J.ECONOMOU,V.NAHOUM,S.D.WEEKS,K.C.GRASTY,I.J.ZENTNER, JRNL AUTH 2 T.M.TOWNSEND,M.W.BHUIYA,S.COCKLIN,P.J.LOLL JRNL TITL A CARRIER PROTEIN STRATEGY YIELDS THE STRUCTURE OF JRNL TITL 2 DALBAVANCIN. JRNL REF J.AM.CHEM.SOC. V. 134 4637 2012 JRNL REFN ISSN 0002-7863 JRNL PMID 22352468 JRNL DOI 10.1021/JA208755J REMARK 2 REMARK 2 RESOLUTION. 1.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.6.2_432 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.78 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.430 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 3 NUMBER OF REFLECTIONS : 77081 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.149 REMARK 3 R VALUE (WORKING SET) : 0.148 REMARK 3 FREE R VALUE : 0.180 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.030 REMARK 3 FREE R VALUE TEST SET COUNT : 3879 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 19.7856 - 3.0132 1.00 7434 362 0.1490 0.1730 REMARK 3 2 3.0132 - 2.3930 1.00 7416 391 0.1452 0.1804 REMARK 3 3 2.3930 - 2.0909 1.00 7406 378 0.1374 0.1709 REMARK 3 4 2.0909 - 1.8999 1.00 7383 403 0.1397 0.1715 REMARK 3 5 1.8999 - 1.7638 1.00 7424 368 0.1203 0.1576 REMARK 3 6 1.7638 - 1.6598 1.00 7366 421 0.1309 0.1745 REMARK 3 7 1.6598 - 1.5768 1.00 7421 403 0.1447 0.1954 REMARK 3 8 1.5768 - 1.5081 1.00 7359 407 0.1658 0.1918 REMARK 3 9 1.5081 - 1.4501 0.99 7389 369 0.1834 0.2008 REMARK 3 10 1.4501 - 1.4001 0.89 6604 377 0.2370 0.2684 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 0.70 REMARK 3 SHRINKAGE RADIUS : 0.38 REMARK 3 K_SOL : 0.39 REMARK 3 B_SOL : 54.72 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.180 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 14.500 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 18.61 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.32770 REMARK 3 B22 (A**2) : -0.32770 REMARK 3 B33 (A**2) : 0.65540 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.008 1541 REMARK 3 ANGLE : 1.317 2099 REMARK 3 CHIRALITY : 0.069 234 REMARK 3 PLANARITY : 0.007 257 REMARK 3 DIHEDRAL : 15.028 599 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3RUN COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-MAY-11. REMARK 100 THE DEPOSITION ID IS D_1000065397. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 25-MAR-11 REMARK 200 TEMPERATURE (KELVIN) : 93 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X6A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 77081 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.400 REMARK 200 RESOLUTION RANGE LOW (A) : 19.800 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 200 DATA REDUNDANCY : 5.480 REMARK 200 R MERGE (I) : 0.07600 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.7500 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.44 REMARK 200 COMPLETENESS FOR SHELL (%) : 87.7 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.65200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.040 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 2LZM REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.18 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.68 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2M AMMONIUM PHOSPHATE, 0.1M TRIS REMARK 280 8.5, 35% MPD, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K, REMARK 280 PH 8.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 64.55333 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 32.27667 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 32.27667 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 64.55333 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 535 LIES ON A SPECIAL POSITION. REMARK 375 HOH B 206 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY A DISACCHARIDE MADE OF D-GLUCOSE REMARK 400 AND VANCOSAMINE. REMARK 400 HERE, VANCOMYCIN IS REPRESENTED BY GROUPING TOGETHER THE REMARK 400 SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) BGC AND RER. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: VANCOMYCIN REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 7 REMARK 400 COMPONENT_2: SUGAR (2-MER) RESIDUES 8 AND 9 REMARK 400 DESCRIPTION: VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, REMARK 400 GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 REMARK 400 AND 9) ON RESIDUE 4. REMARK 400 VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY A DISACCHARIDE MADE OF D-GLUCOSE REMARK 400 AND VANCOSAMINE. REMARK 400 HERE, VANCOMYCIN IS REPRESENTED BY GROUPING TOUGHER THE REMARK 400 SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) BGC AND RER. REMARK 400 REMARK 400 THE VANCOMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: VANCOMYCIN REMARK 400 CHAIN: B, C REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE BGC REMARK 400 COMPONENT_3: RESIDUE RER REMARK 400 DESCRIPTION: VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED REMARK 400 BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2LZM RELATED DB: PDB REMARK 900 STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME REFINED AT 1.7A RESOLUTION REMARK 900 RELATED ID: 3RUL RELATED DB: PDB REMARK 900 RELATED ID: 3RUM RELATED DB: PDB REMARK 900 RELATED ID: 3VFJ RELATED DB: PDB REMARK 900 RELATED ID: 3VFK RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE AUTHORS STATE THAT THESE RESIDUES ARE LIGATED NON-RECOMBINANTLY REMARK 999 WITH NATIVE PROTEIN LIGATION AFTER PROTEIN EXPRESSION AND REMARK 999 PURIFICATION. DBREF 3RUN A 1 164 UNP P00720 LYS_BPT4 1 164 DBREF 3RUN B 1 7 NOR 3RUN NOR00681 1 7 SEQADV 3RUN THR A 54 UNP P00720 CYS 54 ENGINEERED MUTATION SEQADV 3RUN ALA A 97 UNP P00720 CYS 97 ENGINEERED MUTATION SEQADV 3RUN ALA A 164 UNP P00720 LEU 164 ENGINEERED MUTATION SEQADV 3RUN CCS A 165 UNP P00720 SEE REMARK 999 SEQADV 3RUN LYS A 166 UNP P00720 SEE REMARK 999 SEQADV 3RUN DAL A 167 UNP P00720 SEE REMARK 999 SEQADV 3RUN DAL A 168 UNP P00720 SEE REMARK 999 SEQRES 1 A 168 MET ASN ILE PHE GLU MET LEU ARG ILE ASP GLU GLY LEU SEQRES 2 A 168 ARG LEU LYS ILE TYR LYS ASP THR GLU GLY TYR TYR THR SEQRES 3 A 168 ILE GLY ILE GLY HIS LEU LEU THR LYS SER PRO SER LEU SEQRES 4 A 168 ASN ALA ALA LYS SER GLU LEU ASP LYS ALA ILE GLY ARG SEQRES 5 A 168 ASN THR ASN GLY VAL ILE THR LYS ASP GLU ALA GLU LYS SEQRES 6 A 168 LEU PHE ASN GLN ASP VAL ASP ALA ALA VAL ARG GLY ILE SEQRES 7 A 168 LEU ARG ASN ALA LYS LEU LYS PRO VAL TYR ASP SER LEU SEQRES 8 A 168 ASP ALA VAL ARG ARG ALA ALA LEU ILE ASN MET VAL PHE SEQRES 9 A 168 GLN MET GLY GLU THR GLY VAL ALA GLY PHE THR ASN SER SEQRES 10 A 168 LEU ARG MET LEU GLN GLN LYS ARG TRP ASP GLU ALA ALA SEQRES 11 A 168 VAL ASN LEU ALA LYS SER ARG TRP TYR ASN GLN THR PRO SEQRES 12 A 168 ASN ARG ALA LYS ARG VAL ILE THR THR PHE ARG THR GLY SEQRES 13 A 168 THR TRP ASP ALA TYR LYS ASN ALA CCS LYS DAL DAL SEQRES 1 B 7 MLU OMZ ASN GHP GHP OMY 3FG MODRES 3RUN CCS A 165 CYS CARBOXYMETHYLATED CYSTEINE HET CCS A 165 10 HET DAL A 167 5 HET DAL A 168 6 HET MLU B 1 9 HET OMZ B 2 14 HET GHP B 4 11 HET GHP B 5 11 HET OMY B 6 14 HET 3FG B 7 13 HET BGC C 1 22 HET RER C 2 20 HET MPD A 201 8 HET MRD A 202 8 HET PO4 A 203 5 HET TRS A 204 8 HET CL A 205 1 HET IPA A 206 4 HET IPA A 207 4 HET MRD B 103 8 HETNAM CCS CARBOXYMETHYLATED CYSTEINE HETNAM DAL D-ALANINE HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM RER VANCOSAMINE HETNAM MPD (4S)-2-METHYL-2,4-PENTANEDIOL HETNAM MRD (4R)-2-METHYLPENTANE-2,4-DIOL HETNAM PO4 PHOSPHATE ION HETNAM TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL HETNAM CL CHLORIDE ION HETNAM IPA ISOPROPYL ALCOHOL HETSYN BGC BETA-D-GLUCOSE; D-GLUCOSE; GLUCOSE HETSYN RER (1R,3S,4S,5S)-3-AMINO-2,3,6-TRIDEOXY-3-METHYL-ALPHA-L- HETSYN 2 RER ARABINO-HEXOPYRANOSE HETSYN TRS TRIS BUFFER HETSYN IPA 2-PROPANOL FORMUL 1 CCS C5 H9 N O4 S FORMUL 1 DAL 2(C3 H7 N O2) FORMUL 2 MLU C7 H15 N O2 FORMUL 2 OMZ C9 H10 CL N O4 FORMUL 2 GHP 2(C8 H9 N O3) FORMUL 2 OMY C9 H10 CL N O4 FORMUL 2 3FG C8 H9 N O4 FORMUL 3 BGC C6 H12 O6 FORMUL 3 RER C7 H15 N O3 FORMUL 4 MPD C6 H14 O2 FORMUL 5 MRD 2(C6 H14 O2) FORMUL 6 PO4 O4 P 3- FORMUL 7 TRS C4 H12 N O3 1+ FORMUL 8 CL CL 1- FORMUL 9 IPA 2(C3 H8 O) FORMUL 12 HOH *316(H2 O) HELIX 1 1 ASN A 2 GLY A 12 1 11 HELIX 2 2 SER A 38 GLY A 51 1 14 HELIX 3 3 THR A 59 ASN A 81 1 23 HELIX 4 4 LYS A 83 LEU A 91 1 9 HELIX 5 5 ASP A 92 GLY A 107 1 16 HELIX 6 6 GLY A 107 GLY A 113 1 7 HELIX 7 7 PHE A 114 GLN A 123 1 10 HELIX 8 8 ARG A 125 LYS A 135 1 11 HELIX 9 9 SER A 136 THR A 142 1 7 HELIX 10 10 THR A 142 GLY A 156 1 15 HELIX 11 11 TRP A 158 LYS A 162 5 5 SHEET 1 A 3 ARG A 14 LYS A 19 0 SHEET 2 A 3 TYR A 25 GLY A 28 -1 O THR A 26 N TYR A 18 SHEET 3 A 3 HIS A 31 THR A 34 -1 O LEU A 33 N TYR A 25 LINK C ALA A 164 N CCS A 165 1555 1555 1.33 LINK C CCS A 165 N LYS A 166 1555 1555 1.33 LINK C LYS A 166 N DAL A 167 1555 1555 1.33 LINK C DAL A 167 N DAL A 168 1555 1555 1.33 LINK C MLU B 1 N OMZ B 2 1555 1555 1.34 LINK C OMZ B 2 N ASN B 3 1555 1555 1.34 LINK OH OMZ B 2 C5 GHP B 4 1555 1555 1.40 LINK C ASN B 3 N GHP B 4 1555 1555 1.34 LINK C GHP B 4 N GHP B 5 1555 1555 1.33 LINK C3 GHP B 4 OCZ OMY B 6 1555 1555 1.40 LINK O4 GHP B 4 C1 ABGC C 1 1555 1555 1.43 LINK O4 GHP B 4 C1 BBGC C 1 1555 1555 1.43 LINK C GHP B 5 N OMY B 6 1555 1555 1.33 LINK C5 GHP B 5 CG2 3FG B 7 1555 1555 1.42 LINK C OMY B 6 N 3FG B 7 1555 1555 1.33 LINK O2 ABGC C 1 C1 ARER C 2 1555 1555 1.43 LINK O2 BBGC C 1 C1 BRER C 2 1555 1555 1.43 CISPEP 1 GHP B 5 OMY B 6 0 5.99 CRYST1 60.440 60.440 96.830 90.00 90.00 120.00 P 32 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016545 0.009552 0.000000 0.00000 SCALE2 0.000000 0.019105 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010327 0.00000